Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 30, 2026Journal of Clinical Oncology

Coexisting breast cancer and hypertensive disease mortality in U.S. adults increased from an AAMR of 1.65 in 1999 to 6.16 in 2023 (AAPC 5.08%; 95% CI 3.32-6.86).

View Full Paper
Ask AI
Bookmark
Share

Population

U.S. adults with coexisting breast cancer and hypertensive diseases from 1999 to 2023

Design

Cohort

Follow-up

1999 to 2023

Key result

Coexisting breast cancer and hypertensive disease mortality in U.S. adults increased from an AAMR of 1.65 in 1999 to 6.16 in 2023 (AAPC 5.08%; 95% CI 3.32-6.86).

Authors

HMHassan E. MuhammadMSMifrah Rahat Khan SherwaniHAHasan Alajmi

Discussion

Loading...

Member takes

Overview

Mortality involving coexisting breast cancer and hypertensive diseases has accelerated significantly in the U.S., particularly after 2018, highlighting growing cardio-oncologic vulnerabilities.

Key Points

  • This study aims to evaluate long-term mortality trends and disparities among U.S. adults with breast cancer and hypertensive diseases.
  • Evaluated mortality data from CDC WONDER database (1999-2023) using ICD-10 codes for breast cancer and hypertensive diseases.
  • Calculated age-adjusted mortality rates (AAMRs) stratified by demographics and geographic categories.
  • Used Joinpoint regression to analyze temporal trends in mortality rates.
  • AAMRs for those with both conditions increased from 1.65 in 1999 to 6.16 in 2023, with a significant upward trend of 5.08% per year (95% CI: 3.32–6.86).
  • Mortality rose sharply from 2018, with an annual percent change of 22.42% (95% CI: 14.32–31.08).
  • Females had higher mortality rates than males, and significant post-2018 increases were observed across all racial groups.

Study Design

Type

Observational

Multicenter

Yes

Structured PICO

P
Population
U.S. adults with coexisting breast cancer and hypertensive diseases from 1999 to 2023
O
Outcome
Age-adjusted mortality rates (AAMRs) per 100,000 population and temporal trends (annual percent change and average annual percent change)hard clinical

Main Result

Effect estimate: AAPC 5.08% (95% CI 3.32-6.86)

Mortality involving coexisting breast cancer and hypertensive diseases has accelerated significantly in the U.S., particularly after 2018, highlighting growing cardio-oncologic vulnerabilities.

Cite This Study

Muhammad et al. (2026) conducted an observational in Coexisting breast cancer and hypertensive diseases. Coexisting breast cancer and hypertensive disease mortality in U.S. adults increased from an AAMR of 1.65 in 1999 to 6.16 in 2023 (AAPC 5.08%; 95% CI 3.32-6.86).

synapsesocial.com/papers/6a1a81e00307b785094339fchttps://doi.org/10.1200/jco.2026.44.16_suppl.e12716
View Full Paper
Ask AI
Bookmark
Share